Organization | University of Vermont

University of Vermont Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Burlington Vermont United States (1971)

Organization Overview

First Clinical Trial

1983

NCT00000505

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Beth Kirkpatrick | Clinical Science Research Unit, Department of Psychiatry, University of Vermont,1 South Prospect Street, Burlington, VT 05401 | Daniel L Lustgarten | David Lunardini | Department of Obstetrics, Gynecology and Reproductive sciences, Division of Reproductive Endocrinology and Infertility, University of Vermont College of Medicine, Burlington, VT, USA | Fletcher Allen Health Care & University of Vermont | Fletcher Allen Health Care, University of Vermont | Fletcher Allen Health Care / University of Vermont College of Medicine | James BOYD MD | Memory Center, Department of Psychiatry, University of Vermont College of Medicine | Pennington Biodmedical Research Center | Resident | Scott Potenta, MD, PhD | The University of Vermont Medical Center | The Vermont Lung Center at the University of Vermont | University of Vermont | University of Vermont and Pennington Biomedical Research Center | University of Vermont, Burlington | University of Vermont Department of Medicine | University of Vermont Department of Neurology | University of Vermont, Department of Psychiatry | University of Vermont/Feltcher Allen Health Care | University of Vermont/Fletcher Allen Healthcare | University of Vermont & Fletcher Allen Health Care | University of Vermont/Fletcher Allen Health Care,Inc. | University of Vermont Medical Center | University of Vermont Medical Center, Burlington (Vermont, USA) | University of Vermont Medical Center, Vermont | University of Vermont Multiple Sclerosis Center | University of Vermont & State Agricultural College | University of Vermont / United States Principal Investigator | University of Vermont Vaccine Testing Center | University of Vermont / Vermont Children's Hospital | UVM | UVM/FAHC | Vaccine Testing Center, University of Vermont College of Medicine

Active Ingredients

Drugs in Phase 4 Trials (25)

chromium tripicolinate (3 trials)

clonidine (catapres) (1 trial)

diethylpropion hydrochloride (tenuate) (1 trial)

epinephrine (levophed) (1 trial)

fluticasone (cutivate) (1 trial)

human rotavirus, live attenuated (Rotarix) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

lidocaine (xylocaine) (1 trial)

midazolam (versed) (1 trial)

mometasone (elocon) (1 trial)

nicotine (nicorette) (13 trials)

orlistat (xenical) (2 trials)

pioglitazone (actos) (7 trials)

remifentanil (ultiva) (1 trial)

ribavirin (virazole) (1 trial)

ropivacaine (naropin) (1 trial)

sesame oil (1 trial)

sibutramine (meridia) (1 trial)

sitagliptin (januvia) (5 trials)

somatropin (protropin) (1 trial)

telaprevir (incivek) (1 trial)

testosterone (delatestryl) (2 trials)

urea (4 trials)

valproic acid (depakene) (1 trial)

vitamin d3 (2 trials)

Drugs in Phase 3 Trials (30)

acetaminophen (tylenol) (3 trials)

alteplase (Activase) (2 trials)

amlodipine (norvasc) (1 trial)

atorvastatin (lipitor) (2 trials)

beractant (survanta) (1 trial)

bifidobacterium infantis (1 trial)

celecoxib (celebrex) (2 trials)

clomifene (clomid) (2 trials)

colfosceril palmitate (1 trial)

dalfampridine (ampyra) (1 trial)

dapagliflozin (farxiga) (1 trial)

diazepam (valium) (2 trials)

dronabinol (marinol) (3 trials)

follitropin alfa (Gonal-F) (1 trial)

gabapentin (neurontin) (3 trials)

heparin (liquaemin) (1 trial)

hepatitis b immune globulin (human) (BayHep B) (1 trial)

hydrocodone (hycodan) (2 trials)

immune globulin (human) (Gamastan) (2 trials)

Inactivated polio virus - Enhanced (IPOL) (3 trials)

insulin human (humulin) (2 trials)

ketorolac (acuvail) (2 trials)

lactobacillus rhamnosus (1 trial)

letrozole (femara) (3 trials)

lorcaserin (belviq) (4 trials)

losartan (cozaar) (1 trial)

magnesium (1 trial)

palonosetron (aloxi) (1 trial)

sufonylurea (1 trial)

unfractionated heparin (2 trials)

Drugs in Phase 2 Trials (57)

abaloparatide (tymlos) (1 trial)

ace393 (1 trial)

adenovirus-5 encoding human adenylyl cyclase type 6 (1 trial)

amino acids (Freamine) (4 trials)

aminosalicylic acid (Paser) (2 trials)

aprepitant (Emend) (1 trial)

artemisia (2 trials)

azd-1446 (1 trial)

balixafortide (1 trial)

betahistine mesilate (1 trial)

buprenorphine (25 trials)

bupropion (wellbutrin) (3 trials)

caffeine (4 trials)

cangrelor (kengreal) (3 trials)

capecitabine (xeloda) (1 trial)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (2 trials)

clopidogrel (plavix) (1 trial)

docetaxel (taxotere) (2 trials)

dolastatin (1 trial)

donepezil (aricept) (1 trial)

dornase alfa (pulmozyme) (1 trial)

eflornithine (ornidyl) (1 trial)

ephedrine (2 trials)

eribulin (halaven) (1 trial)

estrogen (1 trial)

eucommia (1 trial)

fish oil (Omegavan) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (1 trial)

humanised anti-cd22 antibody (1 trial)

isoprenaline (1 trial)

isosorbide (isordil) (1 trial)

leucovorin (2 trials)

loratadine (claritin) (1 trial)

methylnaltrexone (relistor) (1 trial)

naloxone (narcan) (3 trials)

naltrexone (revia) (3 trials)

ondansetron (zofran) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (1 trial)

pazopanib (votrient) (1 trial)

prasugrel (effient) (2 trials)

prednisone (meticorten) (2 trials)

progesterone (progestasert) (1 trial)

pyridostigmine bromide (mestinon) (1 trial)

rden2delta30-7169 (2 trials)

rituximab (rituxan) (3 trials)

roflumilast (daliresp) (1 trial)

rosuvastatin (crestor) (1 trial)

sodium nitrite (1 trial)

sucrose (1 trial)

ticagrelor (brilinta) (1 trial)

tinzaparin (Innohep) (1 trial)

tv005 (2 trials)

varenicline (chantix) (1 trial)

zonisamide (Zonegran) (2 trials)

Drugs in Phase 1 Trials (33)

acetylsalicylic acid (aspirin) (2 trials)

albuterol (proventil) (2 trials)

aluminum hydroxide (Gaviscon) (1 trial)

bazedoxifene (Duavee) (1 trial)

campylobacter jejuni strain bh-01-0142 (1 trial)

campylobacter jejuni strain cg8421 (2 trials)

cannabis (2 trials)

carmustine (bicnu) (1 trial)

chlorhexidine (hibitane) (1 trial)

cinnamon (1 trial)

cis-diamminedichloroplatinum (1 trial)

conjugated equine estrogens (Premarin) (1 trial)

den1 vaccine (1 trial)

den4 vaccine (1 trial)

diltiazem (cardizem) (1 trial)

Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine (Kinrix) (1 trial)

human fecal microbiota (Reybota) (1 trial)

live, attenuated, dengue serotype 1, 2, 3, 4 virus (1 trial)

live oral poliovirus type 1, 2 and 3 (Trivalent oral polio vaccine - Sabin) (1 trial)

mecamylamine (inversine) (2 trials)

mitoquinol (1 trial)

monovalent oral polio vaccines (mopv1) (MOPV1) (1 trial)

nifurtimox (Lampit) (1 trial)

novel oral polio vaccine type 1 (nopv1) (1 trial)

novel oral polio vaccine type 3 (nopv3) (1 trial)

o6-benzylguanine (1 trial)

rden2/4delta30 vaccine (1 trial)

rden3delta30 (1 trial)

rzikv/d4δ30-713 (1 trial)

tumor specific hybridomas (1 trial)

ursodeoxycholic acid (1 trial)

zinc dichloride (1 trial)

Drugs in Other Trials (32)

acetylcysteine (mucomyst) (1 trial)

amylopectin (1 trial)

amylose (1 trial)

aspartame (1 trial)

blueberry allergenic extract (2 trials)

budesonide (rhinocort) (1 trial)

corticotropin (acthar) (1 trial)

cranberry (1 trial)

cyclophosphamide (cytoxan) (1 trial)

cytarabine (cytosar-u) (1 trial)

eszopiclone (lunesta) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

ferumoxytol (feraheme) (1 trial)

ketamine (ketalar) (1 trial)

lansoprazole (prevacid) (1 trial)

leptin (1 trial)

leptospermum honey (1 trial)

levocarnitine (carnitor) (1 trial)

norethindrone (1 trial)

norgestimate (1 trial)

olive (1 trial)

oryza sativa (1 trial)

perflutren protein-type a microspheres (Optison) (1 trial)

procarbazine (matulane) (1 trial)

quetiapine (seroquel) (1 trial)

rocuronium (zemuron) (1 trial)

sodium chloride (2 trials)

starch (1 trial)

stevia (1 trial)

trigonella foenum-graecum (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Lung Injury (Phase 2)

Alzheimer Disease (Phase 3)

Angina Pectoris (Phase 3)

Anterior Cruciate Ligament Injuries (Phase 3)

Asthma (Phase 4)

Atrophic Vaginitis (Phase 2)

Birth Weight (Phase 3)

Blood Coagulation Disorders (Phase 3)

Body Weight (Phase 3)

Breast Neoplasms (Phase 3)

Bronchopulmonary Dysplasia (Phase 3)

Campylobacter Infections (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Cardiovascular Diseases (Phase 3)

Central Nervous System Neoplasms (Phase 1)

Cocaine-Related Disorders (Phase 2)

Cognitive Dysfunction (Phase 3)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Constipation (Phase 2)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Coronavirus Infections (Phase 3)

Cough (Phase 4)

Critical Illness (Phase 2)

Cystic Fibrosis (Phase 2)

Dengue (Phase 2)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diarrhea (Phase 3)

Disease (Phase 2)

Dyspareunia (Phase 2)

Emergencies (Phase 4)

Fibrosis (Phase 2)

Glioblastoma (Phase 1)

Head and Neck Neoplasms (Phase 2)

Heart Diseases (Phase 3)

Heart Failure (Phase 2)

Hemorrhagic Fevers, Viral (Phase 1)

Hemostatic Disorders (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Hypersensitivity (Phase 3)

Hypertension (Phase 3)

Impulsive Behavior (Phase 4)

Infarction (Phase 3)

Infections (Phase 3)

Infertility (Phase 3)

Insulin Resistance (Phase 3)

Intestinal Diseases (Phase 3)

Ischemia (Phase 3)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lipoma (Phase 2)

Lung Injury (Phase 2)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Marijuana Abuse (Phase 1)

Memory Disorders (Phase 1)

Mental Disorders (Phase 1)

Mood Disorders (Phase 2)

Multiple Sclerosis (Phase 3)

Muscle Weakness (Phase 2)

Myasthenia Gravis (Phase 2)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

Nausea (Phase 3)

Nervous System Neoplasms (Phase 1)

Neuroblastoma (Phase 2)

Obesity (Phase 4)

Opioid-Related Disorders (Phase 2)

Overweight (Phase 3)

Pain, Postoperative (Phase 4)

Parkinson Disease (Phase 4)

Poliomyelitis (Phase 1)

Polycystic Ovary Syndrome (Phase 4)

Polyradiculoneuropathy (Phase 3)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Phase 3)

Psychotic Disorders (Phase 1)

Rectal Neoplasms (Phase 2)

Recurrence (Phase 4)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Respiratory Insufficiency (Phase 2)

Rhinitis (Phase 4)

Rotator Cuff Injuries (Phase 2)

Rotavirus Infections (Phase 4)

Sarcoma (Phase 2)

Schizophrenia (Phase 1)

Sclerosis (Phase 3)

Sepsis (Phase 1)

Severe Acute Respiratory Syndrome (Phase 3)

Severe Dengue (Phase 1)

Shock (Phase 1)

Sinusitis (Phase 4)

Sprue, Tropical (Phase 3)

Substance-Related Disorders (Phase 2)

Syndrome (Phase 3)

Thromboembolism (Phase 3)

Thrombosis (Phase 2)

Tobacco Use Disorder (Phase 2)

Ulcer (Phase 2)

Vaginitis (Phase 2)

Venous Thromboembolism (Phase 3)

Venous Thrombosis (Phase 2)

Vitamin D Deficiency (Phase 4)

Vomiting (Phase 3)

Waldenstrom Macroglobulinemia (Phase 2)

Wounds and Injuries (Phase 2)

Zika Virus Infection (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 196
# of Trial APIs: 177